Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $9.45, but opened at $9.02. Phathom ...

Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call. At this time, all participants are in a listen-only mode. After the presentation, there will be a ...

FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

07, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, ...

Based on the one-year price targets offered by 7 analysts, the average target price for Phathom Pharmaceuticals Inc (NASDAQ:PHAT) is $22.57 with a high estimate of $28 and a low estimate of $12.

FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company ...

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to loss of $0.76 per share a year ago.

Avi Kapoor "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...